2021 Annual Meeting | C39 - Multiple Sclerosis Therapy: Disease-modifying Treatment

Date Monday 04/19/21

Time 08:00 AM - 09:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jacqueline Bernard, MD, FAAN

Moderator(s) Nancy J. Newman, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; feel comfortable creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and provide updates on the impact of COVID-19 disease and vaccination on DMT doses.

CME Available 1.00 CME credit

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
08:00 AM - 08:50 AM EDT	Speaker	MS Therapy: Disease-modifying Treatment Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD
08:50 AM - 09:00 AM EDT	Q&A	Live Q&A Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD

Faculty Disclosures
Jacqueline Bernard, MD, FAAN	Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD	Dr. Lane has nothing to disclose.
Nancy J. Newman, MD, FAAN	Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophth. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Newman has received research support from GenSight. The institution of Dr. Newman has received research support from Santhera. The institution of Dr. Newman has received research support from NINDS/NIH. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��